Egalet (EGLT) Trading Down 0%

Shares of Egalet Corporation (NASDAQ:EGLT) fell 0% during trading on Friday . The company traded as low as $1.06 and last traded at $1.08. 1,138,666 shares changed hands during mid-day trading, a decline of 55% from the average session volume of 2,543,067 shares. The stock had previously closed at $1.08.

Several brokerages have commented on EGLT. Stifel Nicolaus lowered Egalet from a “buy” rating to a “hold” rating and set a $1.50 price objective for the company. in a research report on Wednesday. Gabelli lowered Egalet from a “buy” rating to a “hold” rating in a research report on Thursday, November 9th. Finally, Cantor Fitzgerald set a $7.00 price objective on Egalet and gave the company a “buy” rating in a research report on Friday, December 15th. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the stock. Egalet has a consensus rating of “Hold” and a consensus price target of $6.20.

The company has a debt-to-equity ratio of -3.43, a quick ratio of 2.68 and a current ratio of 2.73. The firm has a market cap of $46.90, a PE ratio of -0.32 and a beta of 0.44.

Institutional investors have recently made changes to their positions in the business. GMT Capital Corp purchased a new position in Egalet during the second quarter valued at $1,281,000. Goldman Sachs Group Inc. raised its position in shares of Egalet by 515.7% in the 2nd quarter. Goldman Sachs Group Inc. now owns 123,454 shares of the specialty pharmaceutical company’s stock worth $293,000 after purchasing an additional 103,402 shares during the last quarter. NJ State Employees Deferred Compensation Plan purchased a new position in shares of Egalet in the 3rd quarter worth about $435,000. HighTower Advisors LLC raised its position in shares of Egalet by 0.9% in the 2nd quarter. HighTower Advisors LLC now owns 268,644 shares of the specialty pharmaceutical company’s stock worth $636,000 after purchasing an additional 2,408 shares during the last quarter. Finally, Virtu KCG Holdings LLC raised its position in shares of Egalet by 87.0% in the 2nd quarter. Virtu KCG Holdings LLC now owns 79,877 shares of the specialty pharmaceutical company’s stock worth $189,000 after purchasing an additional 37,155 shares during the last quarter. 54.05% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: This report was originally published by Community Financial News and is the property of of Community Financial News. If you are viewing this report on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this report can be viewed at https://www.com-unik.info/2018/01/05/egalet-eglt-trading-down-0.html.

Egalet Company Profile

Egalet Corporation is a specialty pharmaceutical company. The Company is engaged in developing, manufacturing and commercializing treatments for pain and other conditions. The Company’s products include OXAYDO and SPRIX Nasal Spray. The Company is developing two late-stage product candidates, ARYMO ER and Egalet-002 using Guardian Technology.

Receive News & Ratings for Egalet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Egalet and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit